Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IL-13 effector functions.

Thomas A Wynn1

  • 1Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. twynn@niaid.nih.gov

Annual Review of Immunology
|March 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution.

JCI insight·2026
Same author

Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.

The Journal of experimental medicine·2024
Same author

Stricturing Crohn's Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions.

Gastroenterology·2023
Same author

Stricturing Crohn's disease single-cell RNA sequencing reveals fibroblast heterogeneity and intercellular interactions.

bioRxiv : the preprint server for biology·2023
Same author

Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation.

Science immunology·2023
Same author

Epithelial-intrinsic defects in TGFβR signaling drive local allergic inflammation manifesting as eosinophilic esophagitis.

Science immunology·2023

Interleukin-13 (IL-13) is a key immune regulator distinct from IL-4, mediating parasite resistance, asthma, and fibrosis. Modulating IL-13 offers therapeutic potential in cancer and inflammatory diseases.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Interleukin-13 (IL-13) was initially recognized for its roles in B cells and monocytes, often considered functionally redundant with IL-4.
  • Emerging research using genetic and antibody-based models reveals distinct and crucial effector functions of IL-13 separate from IL-4.

Purpose of the Study:

  • To delineate the unique effector functions of IL-13 beyond its known roles.
  • To explore the involvement of IL-13 in various physiological and pathological processes, including immunity, inflammation, and cancer.
  • To review the regulatory mechanisms of IL-13 production and function.

Main Methods:

  • Utilized knockout mouse models to investigate IL-13's specific contributions.
  • Employed neutralizing antibodies and novel antagonists to block IL-13 activity.

Related Experiment Videos

  • Reviewed existing literature on IL-13's role in different disease models and its regulatory pathways.

    • Main Results:

    • IL-13 is dominant in type-2 immune responses, crucial for resistance against gastrointestinal nematodes.
    • IL-13 regulates cell-mediated immunity against intracellular pathogens like Leishmania and Listeria.
    • IL-13 is central to allergic asthma pathogenesis, driving eosinophilic inflammation and airway hyperresponsiveness.
    • IL-13 influences cancer progression by modulating apoptosis, tumor growth, and immunosurveillance, suggesting therapeutic targeting.
    • IL-13 is a significant mediator of tissue fibrosis in conditions such as schistosomiasis and asthma.

    Conclusions:

    • IL-13 possesses unique effector functions critical for host defense, inflammation, and tissue remodeling.
    • Targeting IL-13 pathways presents a promising therapeutic strategy for parasitic infections, allergic diseases, fibrosis, and certain cancers.
    • Understanding the complex regulatory network involving IL-13 and its receptors is vital for developing effective immunomodulatory treatments.